BioNTech SE (BNTX) Earnings Yield: 0.50%
Is BioNTech SE’s earnings yield high or low?
BioNTech SE's earnings yield of 0.50% is 95% below its 5-year average of 10.54%, near the low end of its 5-year range (0.34%–40.16%).
The earnings yield for BioNTech SE (BNTX) is 0.50% as of Tuesday, June 9, 2026. It is above its 12-month average by 17.88% (0.42%).
BNTX Earnings Yield Chart
BNTX Average Earnings Yield Chart
BNTX Current vs Average Earnings Yield Chart
BNTX Earnings Yield Metrics
EARNINGS YIELD
0.50%
EARNINGS YIELD AVG TTM
0.42%
EARNINGS YIELD AVG 3Y
3.24%
EARNINGS YIELD AVG 5Y
10.54%
EARNINGS YIELD AVG 10Y
9.80%
EARNINGS YIELD AVG 15Y
9.80%
EARNINGS YIELD AVG 20Y
9.80%
CURRENT VS TTM AVG
+17.88%
CURRENT VS 3Y AVG
-84.59%
CURRENT VS 5Y AVG
-95.26%
CURRENT VS 10Y AVG
-94.90%
CURRENT VS 15Y AVG
-94.90%
CURRENT VS 20Y AVG
-94.90%
BNTX Competitors' Earnings Yield
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioNTech SE (BNTX) | — | 0.50% | 0.42% | 3.24% | 10.54% |
| Mettler-Toledo International Inc. (MTD) | $23.50B | 3.67% | 3.15% | 3.10% | 2.84% |
| Waters Corporation (WAT) | $24.19B | 2.12% | 3.21% | 3.32% | 3.36% |
| Moderna, Inc. (MRNA) | $18.94B | 5.72% | 8.20% | 6.08% | 8.95% |
| Hologic, Inc. (HOLX) | $16.97B | 3.16% | 3.63% | 3.48% | 5.61% |
| Veeva Systems Inc. (VEEV) | $27.37B | 3.35% | 2.28% | 1.91% | 1.64% |
| Biogen Inc. (BIIB) | $29.39B | 4.69% | 6.31% | 5.95% | 5.80% |
| DexCom, Inc. (DXCM) | $30.17B | 2.99% | 2.56% | 1.80% | 1.31% |
| Align Technology, Inc. (ALGN) | $12.76B | 3.35% | 3.51% | 2.66% | 2.47% |
| IQVIA Holdings Inc. (IQV) | $31.09B | 4.33% | 3.95% | 3.55% | 3.02% |
Earnings Yield vs P/E Ratio
Earnings Yield
0.50%
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
- It expresses earnings relative to share price as a percentage
- It can be compared with FCF yield and dividend yield
- It can be compared with bond yields because both are percentages
- It is mathematically the inverse of the P/E ratio
BioNTech SE Earnings Yield Formula & Definition
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
BioNTech SE Earnings Yield FAQ
- What is the earnings yield for BioNTech SE (BNTX)?
- The earnings yield for BNTX stock is 0.50%.
- Is BioNTech SE's earnings yield high or low?
- BioNTech SE's earnings yield of 0.50% is 95% below its 5-year average of 10.54%, near the low end of its 5-year range (0.34%–40.16%).
- What is the TTM average earnings yield for BioNTech SE (BNTX)?
- The TTM average earnings yield for BNTX stock is 0.42%.
- What is the 3Y average earnings yield for BioNTech SE (BNTX)?
- The 3Y average earnings yield for BNTX stock is 3.24%.
- What is the 5Y average earnings yield for BioNTech SE (BNTX)?
- The 5Y average earnings yield for BNTX stock is 10.54%.
- What is the 10Y average earnings yield for BioNTech SE (BNTX)?
- The 10Y average earnings yield for BNTX stock is 9.80%.
- What is the 15Y average earnings yield for BioNTech SE (BNTX)?
- The 15Y average earnings yield for BNTX stock is 9.80%.
- What is the 20Y average earnings yield for BioNTech SE (BNTX)?
- The 20Y average earnings yield for BNTX stock is 9.80%.
BioNTech SE Earnings Yield History
| DATE | EARNINGS YIELD |
|---|---|
| 2026-06-09 | 0.50% |
| 2026-06-08 | 0.50% |
| 2026-06-05 | 0.49% |
| 2026-06-04 | 0.48% |
| 2026-06-03 | 0.49% |
| 2026-06-02 | 0.48% |
| 2026-06-01 | 0.47% |
| 2026-05-29 | 0.45% |
| 2026-05-28 | 0.46% |
| 2026-05-27 | 0.46% |
| 2026-05-26 | 0.47% |
| 2026-05-22 | 0.47% |
| 2026-05-21 | 0.47% |
| 2026-05-20 | 0.48% |
| 2026-05-19 | 0.49% |
| 2026-05-18 | 0.48% |
| 2026-05-15 | 0.48% |
| 2026-05-14 | 0.47% |
| 2026-05-13 | 0.47% |
| 2026-05-12 | 0.46% |
| 2026-05-11 | 0.46% |
| 2026-05-08 | 0.46% |
| 2026-05-07 | 0.46% |
| 2026-05-06 | 0.45% |
| 2026-05-05 | 0.45% |
| 2026-05-04 | 0.43% |
| 2026-05-01 | 0.44% |
| 2026-04-30 | 0.42% |
| 2026-04-29 | 0.42% |
| 2026-04-28 | 0.42% |
| 2026-04-27 | 0.42% |
| 2026-04-24 | 0.41% |
| 2026-04-23 | 0.41% |
| 2026-04-22 | 0.40% |
| 2026-04-21 | 0.39% |
| 2026-04-20 | 0.41% |
| 2026-04-17 | 0.42% |
| 2026-04-16 | 0.42% |
| 2026-04-15 | 0.43% |
| 2026-04-14 | 0.44% |
| 2026-04-13 | 0.44% |
| 2026-04-10 | 0.45% |
| 2026-04-09 | 0.47% |
| 2026-04-08 | 0.47% |
| 2026-04-07 | 0.48% |
| 2026-04-06 | 0.47% |
| 2026-04-02 | 0.47% |
| 2026-04-01 | 0.48% |
| 2026-03-31 | 0.48% |
| 2026-03-30 | 0.50% |
| 2026-03-27 | 0.50% |
| 2026-03-26 | 0.49% |
| 2026-03-25 | 0.48% |
| 2026-03-24 | 0.50% |
| 2026-03-23 | 0.49% |
| 2026-03-20 | 0.48% |
| 2026-03-19 | 0.48% |
| 2026-03-18 | 0.48% |
| 2026-03-17 | 0.45% |
| 2026-03-16 | 0.47% |
| 2026-03-13 | 0.47% |
| 2026-03-12 | 0.48% |
| 2026-03-11 | 0.47% |
| 2026-03-10 | 0.51% |
| 2026-03-09 | 0.42% |
| 2026-03-06 | 0.42% |
| 2026-03-05 | 0.42% |
| 2026-03-04 | 0.41% |
| 2026-03-03 | 0.43% |
| 2026-03-02 | 0.40% |
| 2026-02-27 | 0.39% |
| 2026-02-26 | 0.40% |
| 2026-02-25 | 0.39% |
| 2026-02-24 | 0.39% |
| 2026-02-23 | 0.39% |
| 2026-02-20 | 0.39% |
| 2026-02-19 | 0.39% |
| 2026-02-18 | 0.40% |
| 2026-02-17 | 0.40% |
| 2026-02-13 | 0.41% |
| 2026-02-12 | 0.41% |
| 2026-02-11 | 0.39% |
| 2026-02-10 | 0.39% |
| 2026-02-09 | 0.39% |
| 2026-02-06 | 0.40% |
| 2026-02-05 | 0.41% |
| 2026-02-04 | 0.40% |
| 2026-02-03 | 0.40% |
| 2026-02-02 | 0.39% |
| 2026-01-30 | 0.38% |
| 2026-01-29 | 0.37% |
| 2026-01-28 | 0.37% |
| 2026-01-27 | 0.36% |
| 2026-01-26 | 0.36% |
| 2026-01-23 | 0.37% |
| 2026-01-22 | 0.36% |
| 2026-01-21 | 0.36% |
| 2026-01-20 | 0.41% |
| 2026-01-16 | 0.39% |
| 2026-01-15 | 0.41% |
| 2026-01-14 | 0.39% |
| 2026-01-13 | 0.40% |
| 2026-01-12 | 0.42% |
| 2026-01-09 | 0.43% |
| 2026-01-08 | 0.44% |
| 2026-01-07 | 0.43% |
| 2026-01-06 | 0.44% |
| 2026-01-05 | 0.44% |
| 2026-01-02 | 0.44% |
| 2025-12-31 | 0.45% |
| 2025-12-30 | 0.45% |
| 2025-12-29 | 0.45% |
| 2025-12-26 | 0.45% |
| 2025-12-24 | 0.45% |
| 2025-12-23 | 0.46% |
| 2025-12-22 | 0.47% |
| 2025-12-19 | 0.46% |
| 2025-12-18 | 0.47% |
| 2025-12-17 | 0.47% |
| 2025-12-16 | 0.47% |
| 2025-12-15 | 0.46% |
| 2025-12-12 | 0.45% |
| 2025-12-11 | 0.45% |
| 2025-12-10 | 0.45% |
| 2025-12-09 | 0.45% |
| 2025-12-08 | 0.44% |
| 2025-12-05 | 0.45% |
| 2025-12-04 | 0.45% |
| 2025-12-03 | 0.44% |
| 2025-12-02 | 0.45% |
| 2025-12-01 | 0.44% |
| 2025-11-28 | 0.42% |
| 2025-11-26 | 0.42% |
| 2025-11-25 | 0.43% |
| 2025-11-24 | 0.45% |
| 2025-11-21 | 0.45% |
| 2025-11-20 | 0.44% |
| 2025-11-19 | 0.42% |
| 2025-11-18 | 0.42% |
| 2025-11-17 | 0.42% |
| 2025-11-14 | 0.42% |
| 2025-11-13 | 0.41% |
| 2025-11-12 | 0.38% |
| 2025-11-11 | 0.40% |
| 2025-11-10 | 0.41% |
| 2025-11-07 | 0.42% |
| 2025-11-06 | 0.42% |
| 2025-11-05 | 0.42% |
| 2025-11-04 | 0.41% |
| 2025-11-03 | 0.41% |
| 2025-10-31 | 0.41% |
| 2025-10-30 | 0.41% |
| 2025-10-29 | 0.42% |
| 2025-10-28 | 0.41% |
| 2025-10-27 | 0.41% |
| 2025-10-24 | 0.41% |
| 2025-10-23 | 0.41% |
| 2025-10-22 | 0.40% |
| 2025-10-21 | 0.40% |
| 2025-10-20 | 0.40% |
| 2025-10-17 | 0.41% |
| 2025-10-16 | 0.41% |
| 2025-10-15 | 0.41% |
| 2025-10-14 | 0.42% |
| 2025-10-13 | 0.42% |
| 2025-10-10 | 0.42% |
| 2025-10-09 | 0.41% |
| 2025-10-08 | 0.40% |
| 2025-10-07 | 0.41% |
| 2025-10-06 | 0.41% |
| 2025-10-03 | 0.41% |
| 2025-10-02 | 0.41% |
| 2025-10-01 | 0.42% |
| 2025-09-30 | 0.44% |
| 2025-09-29 | 0.44% |
| 2025-09-26 | 0.44% |
| 2025-09-25 | 0.44% |
| 2025-09-24 | 0.43% |
| 2025-09-23 | 0.44% |
| 2025-09-22 | 0.44% |
| 2025-09-19 | 0.45% |
| 2025-09-18 | 0.45% |
| 2025-09-17 | 0.44% |
| 2025-09-16 | 0.43% |
| 2025-09-15 | 0.44% |
| 2025-09-12 | 0.44% |
| 2025-09-11 | 0.41% |
| 2025-09-10 | 0.43% |
| 2025-09-09 | 0.42% |
| 2025-09-08 | 0.42% |
| 2025-09-05 | 0.38% |
| 2025-09-04 | 0.42% |
| 2025-09-03 | 0.43% |
| 2025-09-02 | 0.43% |
| 2025-08-29 | 0.43% |
| 2025-08-28 | 0.42% |
| 2025-08-27 | 0.42% |
| 2025-08-26 | 0.41% |
| 2025-08-25 | 0.41% |
| 2025-08-22 | 0.39% |
| 2025-08-21 | 0.39% |
| 2025-08-20 | 0.39% |
| 2025-08-19 | 0.39% |
| 2025-08-18 | 0.38% |
| 2025-08-15 | 0.38% |
| 2025-08-14 | 0.38% |
| 2025-08-13 | 0.38% |
| 2025-08-12 | 0.39% |
| 2025-08-11 | 0.39% |
| 2025-08-08 | 0.39% |
| 2025-08-07 | 0.39% |
| 2025-08-06 | 0.39% |
| 2025-08-05 | 0.39% |
| 2025-08-04 | 0.39% |
| 2025-08-01 | 0.40% |
| 2025-07-31 | 0.40% |
| 2025-07-30 | 0.39% |
| 2025-07-29 | 0.39% |
| 2025-07-28 | 0.38% |
| 2025-07-25 | 0.37% |
| 2025-07-24 | 0.38% |
| 2025-07-23 | 0.38% |
| 2025-07-22 | 0.39% |
| 2025-07-21 | 0.39% |
| 2025-07-18 | 0.39% |
| 2025-07-17 | 0.39% |
| 2025-07-16 | 0.38% |
| 2025-07-15 | 0.39% |
| 2025-07-14 | 0.39% |
| 2025-07-11 | 0.38% |
| 2025-07-10 | 0.38% |
| 2025-07-09 | 0.38% |
| 2025-07-08 | 0.39% |
| 2025-07-07 | 0.39% |
| 2025-07-03 | 0.39% |
| 2025-07-02 | 0.40% |
| 2025-07-01 | 0.40% |
| 2025-06-30 | 0.40% |
| 2025-06-27 | 0.40% |
| 2025-06-26 | 0.41% |
| 2025-06-25 | 0.41% |
| 2025-06-24 | 0.41% |
| 2025-06-23 | 0.42% |
| 2025-06-20 | 0.40% |
| 2025-06-18 | 0.41% |
| 2025-06-17 | 0.41% |
| 2025-06-16 | 0.40% |
| 2025-06-13 | 0.40% |
| 2025-06-12 | 0.41% |
| 2025-06-11 | 0.41% |
| 2025-06-10 | 0.40% |
| 2025-06-09 | 0.39% |
| 2025-06-06 | 0.40% |
| 2025-06-05 | 0.39% |
| 2025-06-04 | 0.39% |
| 2025-06-03 | 0.37% |
| 2025-06-02 | 0.38% |
| 2025-05-30 | 0.45% |
| 2025-05-29 | 0.43% |
| 2025-05-28 | 0.44% |
Showing the most recent 260 of 1,365 data points. The chart above shows the full history.
Related Metrics
About BioNTech SE
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ugur Sahin